References
- Stasi R, Bosworth J, Rhodes E, Shannon MS, Willis F, Gordon‐Smith EC. Thrombopoietic agents. Blood Rev 2010;24:179–90.
- de la Cruz‐Vicente F, Alonso‐Rosa D, Urbano‐Ispizua A. Empleo del romiplostin como agente trombopoyético en la púrpura trombocitopénica inmune. Rev Hematol Méx 2010;11:101–4.
- Ruiz‐Argüelles GJ, Ruiz‐Delgado GJ. Enfermedad de injerto contra huésped. Rev Hematol Méx 2010;11(Suppl. 1):31–2.
- Choi SW, Levine JE, Ferrara JL. Pathogenesis and management of graft‐versus‐host disease. Immunol Alergy Clin North Am 2010;30:75–101.
- Sohn SK, Kim DH, Kim JG, Lee NY, Suh JS, Lee KS, et al.. Transplantation outcome in allogeneic PBSCT patients according to a new chronic GVHD grading system, including extensive skin involvement, thrombocytopenia, and progressive‐type onset. Bone Marrow Transplant 2004;34:63–8.
- Gómez‐Almaguer D, Ruiz‐Argüelles GJ, Tarín‐Arzaga LC, González‐Llano O, Jaime‐Pérez JC, López‐Martínez B, et al.. Reduced‐intensity stem cell transplantation in children and adolescents: the Mexican experience. Biol Blood Marrow Transplant 2003;9:157–61.
- Ruiz‐Argüelles GJ, Fernández‐Lara D, Estrada‐Gómez R, Manzano C, Ruiz‐Delgado GJ, Pérez‐Romano B, et al.. Minimal residual disease testing in acute leukemia by flow cytometry immunophenotyping: prognostic significance. Lab Hematol 2007;13:22–6.
- Molineux G, Newland A. Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. Br J Haematol 2010;150:9–20.
- Newland A. Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura. Eur J Haematol Suppl 2009;(71):20–5.
- Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, Gabrilove JL, et al.. Phase II study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood 2010;116:3163–70.